A remote monitoring nurse covering three hundred patients gets, on average, dozens of alerts a shift. Most are not emergencies. A blood pressure cuff read wrong because the patient’s arm was at the wrong height. A pulse oximeter flagged a drop that was really just the sensor slipping off a fingertip. A heart-failure patient’s weight spiked two pounds because they ate at a restaurant the night before. Buried somewhere in that same stream, though, is the one reading that actually matters — the early sign of fluid overload or a rhythm change that, caught a day sooner, keeps someone out of the emergency department. The industry’s answer to sorting one from the other, increasingly, is artificial intelligence. Whether that answer is working yet is a genuinely open question, and it depends heavily on which system, which patient population, and which claim you’re evaluating.

Remote patient monitoring (RPM) has been billable under Medicare for years, and the underlying hardware — Bluetooth cuffs, scales, pulse oximeters, continuous glucose monitors, wearable ECG patches — is mature and cheap. What has changed is the layer sitting between the device and the clinician’s inbox. Vendors are increasingly marketing machine learning models that triage alerts, personalize thresholds per patient, and attempt to predict clinical deterioration before it becomes an emergency, rather than simply flagging every reading that crosses a fixed line. This article looks at what that layer is actually doing, where the evidence is solid, where it is still thin, and what health IT and clinical leaders should be asking before they treat “AI-enabled” as a checkbox.

The Alarm Fatigue Problem AI Is Being Sold to Solve

Alarm fatigue — clinician desensitization to frequent, mostly non-actionable alerts — is well documented in acute care, and it carries over directly into remote monitoring. Systematic reviews of physiologic monitor alarms report that a large majority are non-actionable, with published rates commonly cited in the 74%–99% range depending on the care setting and device configuration, and a body of RPM-specific literature has catalogued dozens of technical approaches aimed at suppressing false and non-actionable alarms rather than just recording them. In some device-monitoring cohorts, false-positive alert rates near 60% have been reported.

The consequence is not just clinician annoyance. When most alerts turn out to be nothing, response times to genuine events slow down, override rates climb, and the cognitive and staffing load of alert triage crowds out higher-value clinical work — the same dynamic patient-safety researchers have described in inpatient alarm fatigue for years, now showing up in remote programs that were supposed to reduce burden, not add to it.

This is the specific gap AI-based triage is meant to close: instead of a single fixed threshold that fires the same way for every patient, an algorithm can weigh trend, context, and patient-specific baseline before deciding whether a reading is worth a human’s attention.

How AI Alert Triage and False-Alarm Reduction Actually Work

Most AI layers marketed for RPM alert management combine a handful of techniques rather than one silver-bullet model:

  • Personalized baselines and adaptive thresholds. Instead of flagging every reading outside a population-wide normal range, the system learns what’s typical for an individual patient over time and flags meaningful deviations from that person’s own pattern.
  • Anomaly detection. Statistical or machine-learning models look for readings or patterns — not just single out-of-range values — that don’t fit the patient’s recent trend.
  • Tiered and contextual routing. Rather than a binary alert/no-alert decision, some systems route lower-confidence or lower-urgency flags to asynchronous review while routing high-confidence, high-acuity signals for immediate escalation.

The evidence that this reduces noise is encouraging in specific, narrow contexts, and much thinner as a general claim. In implantable cardiac monitor (ICM) programs — where devices continuously transmit rhythm data and clinics have historically been swamped with non-actionable transmissions — AI-enhanced algorithms evaluated against independent datasets have been reported to substantially reduce the volume of non-actionable alerts reaching device-clinic staff, with corresponding reductions in review time and staffing burden. Commentary accompanying that research has been notably measured, praising the efficiency gain while flagging that the underlying models are frequently proprietary “black boxes” whose failure modes are not fully visible to the clinicians relying on them — a trade-off worth naming rather than glossing over.

Outside the cardiac-device niche, evidence is more fragmented. A 2023 critical review of alarm-reduction methods for remote monitoring catalogued around 70 peer-reviewed approaches, the majority aimed at suppressing technically false alarms, with a smaller share focused on deterioration prediction or alarm presentation — a sign the field is still an active research area rather than one with a small number of validated, widely deployed approaches.

Predicting Deterioration Before It Becomes an Emergency

The more ambitious use case is not filtering out noise but forecasting risk — flagging a patient trending toward decompensation before a single reading crosses any alarm threshold at all. This is the domain of early warning scores enhanced with machine learning, and it has a longer research track record in inpatient settings that is now migrating toward home-based and ambulatory monitoring.

Machine learning-based early warning models have shown, in multiple studies, improved discrimination over traditional rule-based scores for predicting deterioration events. In one observational study of home-monitored COVID-19 patients using wearable biosensors, a machine-learning-derived deterioration index outperformed a traditional early warning score, and researchers have argued similar approaches are applicable to general medical, surgical, and home-care populations. Separate work on heart failure monitoring has explored using trends in weight, activity, and physiologic data over days to weeks to flag patients at elevated risk of readmission or decompensation, rather than waiting for a single acute reading.

The caveat that runs through nearly all of this literature: performance metrics from a validation study in one population, on one device, with one data pipeline, do not automatically transfer to a different population or care setting. A model tuned on a cohort with rich, clean, continuously streaming data may perform very differently on a home RPM population with intermittent adherence and consumer-grade devices — which is exactly the setting most ambulatory RPM programs operate in.

The Data-Quality Problem Underneath All of It

AI predictions are only as good as the data feeding them, and RPM data is messier than the acute-care telemetry most early warning research was built on. Wearable and home-device data streams commonly suffer from sensor noise, motion artifact, dropped connections, and inconsistent patient adherence to wear-and-transmit schedules — and preprocessing pipelines to clean, normalize, and standardize that data across device types are, by researchers’ own assessment, not yet fully mature. Techniques such as signal filtering to remove motion artifact and imputation methods to handle missing readings are active areas of methods development, not solved problems with a single accepted standard.

This matters for AI triage specifically because a model trained to distinguish “real” alerts from noise is themselves vulnerable to the same noise it’s meant to filter. A poorly calibrated model facing degraded input data can fail in either direction — suppressing a genuine deterioration signal because it resembles sensor artifact, or amplifying artifact into a false alert because it deviates from a patient’s usual (also noisy) baseline. Programs evaluating AI-enabled RPM tools should ask vendors directly how their models were validated against real-world data quality issues — missed transmissions, device swaps, low-adherence patients — rather than only against curated research datasets.

Reimbursement Is Still Catching Up

Medicare’s RPM billing structure was not built with AI-driven triage or prediction in mind, and reimbursement policy has been a moving target independent of the AI question. CMS has proposed and continued to revise core RPM requirements — including the long-standing rule that required at least 16 days of transmitted data within a 30-day period before the device-supply code could be billed at all. In 2025 rulemaking for the 2026 Medicare Physician Fee Schedule, CMS proposed a new, lower-threshold device code covering as few as two to fifteen days of data in a 30-day period, alongside broader acceptance of communication modalities and a general acknowledgment of AI-and-wearable-driven technology as part of the direction RPM is heading.

None of the current CPT codes for RPM treatment management (99457/99458) distinguish between clinical staff time spent reviewing an AI-triaged alert queue and time spent reviewing an unfiltered data stream — the billing framework is agnostic to whether AI helped a clinician get there faster. That creates a real incentive gap: a program that invests in AI triage to make clinician time more efficient does not currently get paid more (or differently) for doing so, and there is no dedicated reimbursement pathway that recognizes AI-generated risk scores or predictions as a distinct, separately billable clinical service. Because CMS rulemaking changes annually and was still in proposed-rule status at the time of this writing, program leaders should confirm current requirements against the finalized Physician Fee Schedule rather than treating any specific threshold as settled.

FDA Oversight of AI-Enabled Monitoring Devices

Regulatory treatment of AI-enabled monitoring software has been evolving in parallel. The FDA’s January 2025 draft guidance, “Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations,” lays out expectations across the total product lifecycle — including data lineage, bias evaluation, human-AI interaction design, and post-market performance monitoring — for devices that incorporate AI or machine learning components. That builds on the agency’s finalized framework for Predetermined Change Control Plans (PCCPs), which allow manufacturers to pre-specify how an algorithm may be updated over time (for example, via retraining on new data) without triggering a new marketing submission for every change, provided the plan itself was reviewed and authorized up front.

This matters directly for AI-enabled RPM because many of the algorithms doing alert triage or deterioration prediction are designed to improve or retrain as they ingest more data — the opposite of a “locked” algorithm that behaves identically forever. A PCCP framework, in principle, lets that kind of continuous improvement happen within FDA-authorized bounds instead of outside regulatory visibility entirely. In August 2025, the FDA joined regulators in Canada and the UK in publishing shared guiding principles for PCCPs specifically for machine-learning-enabled devices, signaling that regulators view algorithm drift and post-market change management as a priority area rather than a settled one. Health IT leaders evaluating AI-enabled RPM products should ask vendors directly whether the AI component is FDA-cleared as part of the device, offered as separate clinical decision support, or marketed without a specific regulatory clearance at all — those are materially different risk and liability postures.

What This Means for Program Design Today

Taken together, the current state of evidence suggests a few practical conclusions for health systems evaluating AI-enabled RPM in 2025:

  • AI-assisted alert triage has the strongest evidence in narrow, high-volume alert contexts — implantable cardiac device monitoring being the clearest example — where the sheer volume of non-actionable transmissions made manual review unsustainable in the first place.
  • Deterioration-prediction models are promising but population-specific. Results from one device, dataset, or clinical population should not be assumed to generalize, and programs should ask for validation evidence from populations that resemble their own.
  • Data quality is the limiting factor, not model sophistication. A more advanced algorithm cannot fully compensate for noisy, intermittent, or inconsistent input data from consumer-grade home devices.
  • Reimbursement has not caught up to the technology. Programs should not assume AI triage unlocks new billing codes or higher payment — current CPT structures are agnostic to how the alert queue was generated.
  • Regulatory status varies by product, and “AI-enabled” is not a single, uniform claim — some tools carry FDA clearance for the AI function itself, others do not.

None of this is a reason to avoid AI-enabled monitoring tools. It is a reason to evaluate them the way any new clinical technology should be evaluated: by asking for validation evidence specific to your patient population, by understanding exactly what the algorithm is and isn’t cleared to do, and by treating vendor marketing claims about “fewer false alarms” as a hypothesis to test against your own data rather than a guarantee.

This article is intended for health IT and clinical operations audiences and does not constitute medical advice. Organizations evaluating AI-enabled monitoring tools for a specific patient population should consult current FDA guidance, CMS rulemaking, and their own clinical and compliance teams before deployment.

Frequently Asked Questions

Does AI actually reduce false alarms in remote patient monitoring?

In some contexts, yes — particularly implantable cardiac monitoring, where AI-enhanced algorithms have been shown to meaningfully cut non-actionable alert volume in validation studies. Evidence is thinner and more fragmented for general home RPM, where a large and growing research literature is still testing different approaches rather than converging on one proven method.

Can AI predict patient deterioration before symptoms appear?

Machine learning-based early warning models have outperformed traditional rule-based scores in several studies, including home-monitored populations, by analyzing trends rather than single readings. However, performance is population- and dataset-specific, so results from one study don’t automatically apply to a different patient group or device setup.

Does Medicare pay more for AI-enabled remote monitoring?

Not currently. Existing RPM treatment-management CPT codes (99457/99458) are billed based on clinical staff time and interaction, regardless of whether an AI system helped triage the alert queue. There is no dedicated reimbursement code recognizing AI-generated risk scores as a separately billable service as of this writing.

Is AI-enabled remote monitoring software regulated by the FDA?

It depends on the product. Some AI functions are built into an FDA-cleared device and fall under the agency’s AI/ML device software guidance, including rules for how algorithms may be updated post-market. Other analytics or triage tools are offered as software layered on top of monitoring data without a specific FDA clearance for the AI component — health systems should confirm a given tool’s actual regulatory status rather than assume “AI-enabled” implies clearance.

What’s the biggest barrier to trusting AI alerts in remote monitoring?

Data quality is the most frequently cited limiting factor. Home and wearable devices produce noisier, more intermittent data than clinical-grade telemetry, and preprocessing methods to clean that data are still maturing — which means an AI model is only as reliable as the signal it’s given to work with.